The present invention refers to a system for the process of synthesis of zeolite nanoparticles in continuous flow wherein the processes of mixing, aging and crystallization are integrated, to reduce the synthesis time. The system has a microfluidic device of the 3D crossing channels micromixer type, consisting of microchannels built in series, used to generate the reaction mixture; buffer system with addition of seeds; and a heated tubular reactor which, in turn, is used for crystallization, which takes place through a continuous hydrothermal process.

The present invention refers to a system for the process of synthesis of zeolite nanoparticles in continuous flow wherein the processes of mixing, aging and crystallization are integrated, to reduce the synthesis time. The system has a microfluidic device of the 3D crossing channels micromixer type, consisting of microchannels built in series, used to generate the reaction mixture; buffer system with addition of seeds; and a heated tubular reactor which, in turn, is used for crystallization, which takes place through a continuous hydrothermal process.

The present invention provides a magnesium-modified ultra-stable rare earth type Y molecular sieve and the preparation method thereof, which method is carried out by subjecting a NaY molecular sieve as the raw material to a rare earth exchange and a dispersing pre-exchange, then to an ultra-stabilization calcination treatment, and finally to a magnesium modification. The molecular sieve comprises 0.2 to 5% by weight of magnesium oxide, 1 to 20% by weight of rare earth oxide, and not more than 1.2% by weight of sodium oxide, and has a crystallinity of 46 to 63%, and a lattice parameter of 2.454 nm to 2.471 nm. In contrast to the prior art, in the molecular sieve prepared by this method, rare earth ions are located in sodalite cages, which is demonstrated by the fact that no rare earth ion is lost during the reverse exchange process. Moreover, the molecular sieve prepared by such a method has a molecular particle size D(v,0.5) of not more than 3.0 μm and a D(v,0.9) of not more than 20 μm. Such a molecular sieve has both high stability and high selectivity for the target product, while cracking catalysts using the molecular sieve as an active component is characterized by a high heavy-oil-conversion capacity and a high yield of valuable target products.

A family of new crystalline molecular sieves designated SSZ-91 is disclosed, as are methods for making SSZ-91 and uses for SSZ-91. Molecular sieve SSZ-91 is structurally similar to sieves falling within the ZSM-48 family of molecular sieves, and is characterized as: (1) having a low degree of faulting, (2) a low aspect ratio that inhibits hydrocracking as compared to conventional ZSM-48 materials having an aspect ratio of greater than 8, and (3) is substantially phase pure.

An object of the present invention is to provide an AFX zeolite having a novel structure. An AFX zeolite having a lattice spacing d of a (004) plane being not less than 4.84 Å and not greater than 5.00 Å, and a molar ratio of silica to alumina being not less than 10 and not higher than 32. Such an AFX zeolite can be produced by a production method comprising a crystallization step of crystallizing a composition at a temperature of not lower than 160° C.; the composition containing a silicon source, an aluminum source, a 1,3-di(1-adamantyl)imidazolium cation, and an alkali metal; a molar ratio of hydroxide ions to silica being less than 0.25 or a molar ratio of silica to alumina being not higher than 27; and a molar ratio of the 1,3-di(1-adamantyl)imidazolium cation to silica being less than 0.20.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

Zeolites having highly dispersed bimetallic clusters, uniformly distributed in size and composition, encapsulated therein are disclosed. Metal encapsulation and alloying is conferred by introducing ligated metal cation precursors into zeolite synthesis gels, which are subsequently crystallized hydrothermally to form zeolites with metal cations occluded in the pores. The ligated cations are anchored to the zeolite framework via siloxane bridges which enforces their uniform dispersion throughout the zeolite crystals. Treatment of the crystallized zeolites in O.sub.2 and then H.sub.2 forms bimetallic clusters, which remain narrowly distributed in size and composition.

The present disclosure is directed to a potassium-form MER framework type zeolite, a MER framework type zeolite having a stick-like morphology, wherein the potassium is present as K.sup.+ in extra-framework locations. The zeolite is essentially free of an extra-framework cation other than potassium.

Disclosed herein are modified zeolites and methods for making modified zeolites. In one or more embodiments disclosed herein, a modified zeolite may include a microporous framework including a plurality of micropores having diameters of less than or equal to 2 nm. The microporous framework includes at least silicon atoms and oxygen atoms. The modified zeolite may further include organometallic moieties each bonded to bridging oxygen atoms. The organometallic moieties include a hafnium atom. The hafnium atom is bonded to a bridging oxygen atom, and bridging oxygen atom bridges the hafnium atom of the organometallic moiety and a silicon atom of the microporous framework.